Korean Circ J.  2023 Oct;53(10):710-719. 10.4070/kcj.2023.0089.

Association Between Plasma Homocysteine Level and Mortality: A Mendelian Randomization Study

• Choi CK
• Kweon SS
• Lee YH
• Nam HS
• Choi SW
• Kim HY
• Shin MH

• KMID: 2546995
• DOI: http://doi.org/10.4070/kcj.2023.0089

Abstract

Background and Objectives
In previous studies, high homocysteine levels were associated with high cardiovascular mortality. However, these results were inconsistent with those of randomized controlled trials. We aimed to evaluate the causal role of homocysteine on allcause and cardiovascular mortality using Mendelian randomization (MR) analysis.
Methods
This study included the 10,005 participants in the Namwon Study. In conventional observational analysis, age, sex, survey years, lifestyles, body mass index, comorbidities, and serum folate level were adjusted using multivariate Cox proportional regression. MR using 2-stage least squares regression was used to evaluate the association between genetically predicted plasma homocysteine levels and mortality. Age, sex, and survey years were adjusted for each stage. The methylenetetrahydrofolate reductase (MTHFR) polymorphism was used as an instrumental variable for predicting plasma homocysteine levels.
Results
Observed homocysteine levels were positively associated with all-cause (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.26–1.54) and cardiovascular (HR, 1.62; 95% CI, 1.28–2.06) mortality when plasma homocysteine levels doubled. However, these associations were not significant in MR analysis. The HRs of doubling genetically predicted plasma homocysteine levels for all-cause and cardiovascular mortality were 0.99 (95% CI, 0.62–1.57) and 1.76 (95% CI, 0.54–5.77), respectively.
Conclusions
This MR analysis did not support a causal role for elevated plasma homocysteine concentrations in premature deaths.

Keyword

Cohort studies; Homocysteine; Mendelian randomization analysis; Mortality; Survival analysis

Reference

1. Sundström J, Sullivan L, D’Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension. 2003; 42:1100–1105. PMID: 14597642.

2. Sudchada P, Saokaew S, Sridetch S, Incampa S, Jaiyen S, Khaithong W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012; 98:151–158. PMID: 22727498.

3. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. 2008; 83:1203–1212. PMID: 18990318.

4. Lehotský J, Tothová B, Kovalská M, et al. Role of homocysteine in the ischemic stroke and development of ischemic tolerance. Front Neurosci. 2016; 10:538. PMID: 27932944.

5. Fan R, Zhang A, Zhong F. Association between homocysteine levels and all-cause mortality: a dose-response meta-analysis of prospective studies. Sci Rep. 2017; 7:4769. PMID: 28684797.

6. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011; 378:584–594. PMID: 21803414.

7. Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res. 2018; 41:372–383. PMID: 29552692.

8. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170:1622–1631. PMID: 20937919.

9. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008; 27:1133–1163. PMID: 17886233.

10. Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012; 9:e1001177. PMID: 22363213.

11. Miao L, Deng GX, Yin RX, et al. No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: a Mendelian randomization study. Eur J Prev Cardiol. 2021; 28:227–234. PMID: 33838042.

12. Larsson SC, Traylor M, Markus HS. Homocysteine and small vessel stroke: A Mendelian randomization analysis. Ann Neurol. 2019; 85:495–501. PMID: 30785218.

13. Kweon SS, Shin MH, Jeong SK, et al. Cohort profile: the Namwon Study and the Dong-gu Study. Int J Epidemiol. 2014; 43:558–567. PMID: 23505254.

14. Kweon SS, Lee YH, Jeong SK, et al. Methylenetetrahydrofolate reductase 677 genotype-specific reference values for plasma homocysteine and serum folate concentrations in Korean population aged 45 to 74 years: the Namwon Study. J Korean Med Sci. 2014; 29:743–747. PMID: 24851035.

15. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021; 385:1737–1749. PMID: 34554658.

16. Park JY, Nicolas G, Freisling H, et al. Comparison of standardised dietary folate intake across ten countries participating in the European Prospective Investigation into Cancer and Nutrition. Br J Nutr. 2012; 108:552–569. PMID: 22040523.

17. McLean E, de Benoist B, Allen LH. Review of the magnitude of folate and vitamin B12 deficiencies worldwide. Food Nutr Bull. 2008; 29:S38–S51. PMID: 18709880.

18. Rogers LM, Cordero AM, Pfeiffer CM, et al. Global folate status in women of reproductive age: a systematic review with emphasis on methodological issues. Ann N Y Acad Sci. 2018; 1431:35–57. PMID: 30239016.

19. Wilcken B, Bamforth F, Li Z, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003; 40:619–625. PMID: 12920077.

20. Esfahani ST, Cogger EA, Caudill MA. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc. 2003; 103:200–207. PMID: 12589326.

21. Wang WW, Wang XS, Zhang ZR, He JC, Xie CL. A meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and hyperhomocysteinemia. Front Pharmacol. 2017; 8:585. PMID: 28912716.

22. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One. 2011; 6:e16473. PMID: 21311765.

23. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016; 5:e003768. PMID: 27528407.

24. Zhao M, Wang X, He M, et al. Homocysteine and stroke risk: modifying effect of methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention. Stroke. 2017; 48:1183–1190. PMID: 28360116.

25. Borges MC, Hartwig FP, Oliveira IO, Horta BL. Is there a causal role for homocysteine concentration in blood pressure? A Mendelian randomization study. Am J Clin Nutr. 2016; 103:39–49. PMID: 26675774.

26. Kumar J, Ingelsson E, Lind L, Fall T. No evidence of a causal relationship between plasma homocysteine and type 2 diabetes: a Mendelian randomization study. Front Cardiovasc Med. 2015; 2:11. PMID: 26664883.

27. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42:1497–1501. PMID: 24159078.

28. Lee Y, Park S. Serum folate levels and hypertension. Sci Rep. 2022; 12:10071. PMID: 35710919.